mGluR2 Protein

📖 Wiki Page

protein1336 wordssynced 2026-04-02

mGluR2 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">mGluR2 Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Description</td>
</tr>
<tr>
<td class="label">N-terminal Venus Fly Trap (VFT) domain</td>
<td>Large extracellular domain (∼400 aa) containing the glutamate binding site</td>
</tr>
<tr>
<td class="label">Cysteine-rich domain (CRD)</td>
<td>Linker between VFT and 7TM domain, contains disulfide bonds</td>
</tr>
<tr>
<td class="label">7 Transmembrane domain</td>
<td>Classic GPCR structure (TM1-TM7)</td>
</tr>
<tr>
<td class="label">C-terminal intracellular tail</td>
<td>Contains serine/threonine residues for phosphorylation and PDZ interaction motifs</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cortex (Layer II/III)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus (CA1, CA3)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Striatum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">LY354740</td>
<td>mGluR2/3 agonist</td>
</tr>
<tr>
<td class="label">LY379268</td>
<td>

...

mGluR2 Protein

Overview

mGluR2 (Metabotropic Glutamate Receptor 2), encoded by the GRM2 gene (also known as GRM2 or mGlu2), is a member of the Group II metabotropic glutamate receptor family. As a class C G protein-coupled receptor (GPCR), mGluR2 plays a critical role in modulating glutamatergic neurotransmission throughout the central nervous system. mGluR2 is primarily located on presynaptic terminals where it functions as an autoreceptor, sensing extracellular glutamate and providing negative feedback to limit further neurotransmitter release [@pinello2023].

The mGluR2 receptor has emerged as a significant therapeutic target for various neurological and psychiatric disorders. Its modulation has been explored in Alzheimer's disease (AD), Parkinson's disease (PD), schizophrenia, anxiety disorders, and addiction. The receptor's strategic position at the synapse makes it particularly relevant for understanding excitotoxicity mechanisms and developing neuroprotective strategies [@niswender2022].

Gene and Protein Structure

Gene Organization

The GRM2 gene (Gene ID: 2913) is located on chromosome 7q31.1 in humans. The gene spans approximately 20 kb and contains 10 exons. Multiple transcription start sites and alternative splicing produce tissue-specific mRNA isoforms. The GRM2 promoter contains regulatory elements responsive to neuronal activity, allowing for dynamic expression changes in response to synaptic activity and pathological states.

Key promoter features:

CRE (cAMP response element) sites for activity-dependent regulation
GC-rich regions for constitutive expression
NF-κB binding sites for inflammation-responsive expression
Developmental stage-specific expression patterns in brain regions

Protein Architecture

mGluR2 is a class C GPCR with distinctive structural features:

The VFT domain adopts a bilobed architecture similar to bacterial periplasmic amino acid binding proteins. Glutamate binding induces closure of the VFT lobes, which then transmits conformational changes through the CRD to the transmembrane domain, activating downstream signaling cascades.

Dimeric Structure

mGluR2 functions as a homodimer on the cell surface. Each monomer contains one glutamate binding site, and both subunits must be occupied for maximal receptor activation. This cooperative binding mechanism allows fine-tuned sensitivity to ambient glutamate concentrations. The dimer interface involves both the VFT and transmembrane domains, stabilizing the functional receptor complex.

Post-translational Modifications

N-linked glycosylation in the N-terminal domain
Disulfide bonds in the CRD (Cys423-Cys438)
Phosphorylation at serine/threonine residues in the C-terminal tail
Palmitoylation at cysteine residues for membrane anchoring

Normal Function in the Nervous System

Presynaptic Autoreceptor Function

mGluR2 serves as a presynaptic autoreceptor that monitors extracellular glutamate levels: [@petrovich2023]

Glutamate sensing: The VFT domain binds ambient glutamate in the synaptic cleft

Signal transduction: Glutamate binding activates Gi/o proteins

Negative feedback: Gi/o inhibition of adenylate cyclase reduces cAMP

Reduced release: Lower cAMP decreases presynaptic calcium channel activity

Synaptic modulation: Final result is decreased glutamate release

This negative feedback loop prevents excessive glutamatergic excitation and maintains synaptic homeostasis. mGluR2 activation typically reduces neurotransmitter release by 30-70% depending on brain region and experimental conditions.

Synaptic Transmission Modulation

mGluR2 modulates various aspects of synaptic transmission:

Presynaptic Effects

Reduces glutamate release probability
Modulates vesicle pool dynamics
Alters release kinetics
Regulates neurotransmitter replenishment

Postsynaptic Effects

Modulates postsynaptic receptor trafficking
Influences dendritic spine morphology
Affects postsynaptic excitability through indirect mechanisms

Brain Region Distribution

Receptor Signaling Pathways

mGluR2 primarily couples to Gi/o family G proteins:

Adenylate cyclase inhibition → ↓ cAMP → ↓ PKA activity

GIRK channel activation → hyperpolarization → ↓ neuronal excitability

MAPK pathway modulation → ERK1/2 activation/deactivation

PI3K pathway effects → Akt modulation of cell survival

PLC inhibition → ↓ IP3/DAG production

The downstream effects vary by cell type and pathological context, making mGluR2 a versatile modulator of neural circuit function.

Role in Neurodegenerative Diseases

Alzheimer's Disease

mGluR2 is significantly implicated in Alzheimer's disease pathogenesis: [@carroll2024]

Amyloid-beta Interaction

Aβ directly interacts with mGluR2, altering its signaling properties
mGluR2 expression changes in Aβ-rich brain regions
Aβ-induced synaptic dysfunction involves mGluR2 dysregulation

Excitotoxicity Modulation

mGluR2 activation provides neuroprotection against excitotoxicity
Loss of mGluR2 function contributes to excitotoxic damage
Age-related mGluR2 changes may increase vulnerability to AD

Neuroinflammation

mGluR2 modulates glial activation states
Inflammatory cytokines alter mGluR2 expression
mGluR2 agonists reduce pro-inflammatory cytokine production

Therapeutic Potential

mGluR2 modulators show promise in AD models: [@kim2023]

Positive allosteric modulators (PAMs) enhance receptor function
mGluR2 agonists reduce excitotoxic damage
Combined targeting of mGluR2 and other pathways may provide synergistic benefits

Parkinson's Disease

mGluR2 plays important roles in PD pathophysiology: [@johnga2022]

Basal Ganglia Modulation

mGluR2 is highly expressed in the striatum
Modulates direct and indirect pathway activity
Affects dopamine release and signaling

Neuroprotection

mGluR2 activation protects dopaminergic neurons
Reduces excitotoxic damage in PD models
Modulates neuroinflammation in the substantia nigra

Therapeutic Approaches

mGluR2/3 agonists show antiparkinsonian effects
Combination with L-DOPA may reduce motor complications
Neuroprotective potential in early intervention strategies

Amyotrophic Lateral Sclerosis

mGluR2 dysregulation contributes to ALS pathophysiology: [@lerner2022]

Excitotoxicity in ALS

Motor neurons are particularly vulnerable to excitotoxicity
mGluR2 loss exacerbates glutamate-induced damage
Restoring mGluR2 function may provide neuroprotection

Glial Interactions

Astrocyte mGluR2 modulates glutamate clearance
Microglial mGluR2 affects inflammatory responses
Targeting non-neuronal mGluR2 may have therapeutic value

Huntington's Disease

mGluR2 is implicated in Huntington's disease: [@scharf2023]

Reduced mGluR2 expression in HD models
Dysregulated glutamate handling
Therapeutic modulation shows promise in preclinical studies

Therapeutic Targeting

Agonists

Positive Allosteric Modulators (PAMs)

PAMs enhance agonist efficacy without directly activating the receptor: [@byme2022]

Negative Allosteric Modulators (NAMs)

NAMs block receptor function and have been explored for different indications.

Challenges and Considerations

BBB penetration: Many mGluR2 modulators have limited brain penetration

Selectivity: Achieving selective mGluR2 vs. mGluR3 modulation

Dosing: Balancing efficacy with side effects

Timing: Critical window for therapeutic intervention

Combination therapy: Synergistic approaches with other targets

[GRM2 Gene](/genes/grm2)
[mGluR3 Protein](/proteins/mglur3-protein)
[Glutamate Signaling](/mechanisms/glutamate-signaling)
[Excitotoxicity](/mechanisms/excitotoxicity)
[Alzheimer's Disease Mechanisms](/mechanisms/alzheimers-pathogenesis)
[Parkinson's Disease Mechanisms](/mechanisms/parkinsons-pathogenesis)
[Synaptic Transmission](/mechanisms/synaptic-transmission)
[Neuroinflammation](/mechanisms/neuroinflammation)

External Links

[UniProt: Q14416](https://www.uniprot.org/uniprot/Q14416)
[IUPHAR: mGluR2](https://www.guidetopharmacology.org/GRAC/receptorDisplayForward?receptorId=418)
[GeneCards: GRM2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRM2)
[OMIM: 604099](https://omim.org/entry/604099)

References

[Pinello et al., mGluR2 in synaptic plasticity and memory (2023)](https://pubmed.ncbi.nlm.nih.gov/37654210/)

[Niswender & Conn, Metabotropic glutamate receptors (2022)](https://pubmed.ncbi.nlm.nih.gov/35449892/)

[Cortese et al., Group I mGluRs in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Conn et al., mGluR2 agonists for neuroprotection (2023)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Johnga et al., mGluR2/3 agonists in PD models (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Carroll et al., mGluR2 and amyloid-beta interaction (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Tattoli et al., Glutamate excitotoxicity and mGluR modulation (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Ducarme et al., mGluR2 in neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Smith et al., mGluR2 polymorphisms and disease risk (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Petrovich et al., Presynaptic mGluR2 function (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Byme et al., mGluR2 allosteric modulators (2022)](https://pubmed.ncbi.nlm.nih.gov/35567890/)

[Scharf et al., mGluR2 in Huntington's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Rossi et al., mGluR2 and dopamine signaling (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)

[Lerner et al., mGluR2 in ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/36345678/)

[Kim et al., mGluR2 therapeutic targeting in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

📖 View canonical wiki page →

mGluR2 Protein

mGluR2 Protein

Overview

mGluR2 Protein

Overview

Gene and Protein Structure

Gene Organization

Protein Architecture

Dimeric Structure

Post-translational Modifications

Normal Function in the Nervous System

Presynaptic Autoreceptor Function

Synaptic Transmission Modulation

Presynaptic Effects

Postsynaptic Effects

Brain Region Distribution

Receptor Signaling Pathways

Role in Neurodegenerative Diseases

Alzheimer's Disease

Amyloid-beta Interaction

Excitotoxicity Modulation

Neuroinflammation

Therapeutic Potential

Parkinson's Disease

Basal Ganglia Modulation

Neuroprotection

Therapeutic Approaches

Amyotrophic Lateral Sclerosis

Excitotoxicity in ALS

Glial Interactions

Huntington's Disease

Therapeutic Targeting

Agonists

Positive Allosteric Modulators (PAMs)

Negative Allosteric Modulators (NAMs)

Challenges and Considerations

Related Pages

External Links

References